Guidance
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
In October 2018, we withdrew recommendations on preventing thrombosis because they have been replaced by the NICE guideline on venous thromboembolism in over 16s.
Recommendations
This guideline includes recommendations on:
- communication and support
- laboratory investigations
- imaging investigations
- managing newly-diagnosed and relapsed myeloma
- preventing and managing bone disease and other complications
- monitoring
Who is it for?
- Healthcare professionals responsible for diagnosing and managing myeloma
- Hospitals that provide myeloma management
- Commissioners of specialised services
- People with myeloma, their families and carers
Is this guideline up to date?
June 2023: We have found no new evidence that affects the recommendations. For more information, see the surveillance decision.
Guideline development process
How we develop NICE guidelines
Your responsibility
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.